ESPE Abstracts

Background: Early TS diagnosis permits early GH start and estradiol (E²) supplementation approaching adult height (AH) at normal age and within a normal range. However, higher age at diagnosis is still a challenge.

Objective and hypotheses: The hypothesis from our long-term trials will result in knowledge for personalized treatment in order to obtain a psychological acceptable age at onset of puberty and still an attained AH within normal range for TS girls.

Method: 132 prepubertal TS girls (3–9/9–16 years) were randomised into national multicenter studies with GH treatment (33/67 μg/kg per day) in combination with possible oxandrolone from 11 years and oral/transdermal estradiol. Subjects were followed until AH.

Results: Height_SDS at start was -2.8 (vs non-TS) in all subgroups. Age at onset of puberty (years) and AH (cm) was for GH_33young 14.7, 153.7; GH_67young 13.0, 157.2; GH_33old 15.2, 156.5; GH_67old 14.1, 159.9. Oxandrolone was used in 94% of GH₃₃ and in 54% of the GH₆₇ group. Pubertal growth was 3.3, 7.7, 7.2 and 9.2 cm, respectively. In multivariate analysis the factors GH dose, age and duration of puberty(+) all had high impact on AH.

Conclusion: Younger age at start with higher GH dose results in increased prepubertal height gain, permitting puberty at normal age (2 years before low dose) and an AH within normal range. The girl diagnosed at higher age can still attain an acceptable age at puberty onset and AH – by using higher GH dose, oxandrolone and slow oestradiol dose increment. Thus it is now possible to optimise the treatment tools GH dose, oxandrolone and estradiol in a personalised approach.

Conflict of interest: BK has received lecture fee from Sandoz, Pfizer and Novo Nordisk.

Funding information: Growth hormone was partly provided (higher than standard dose) by Pharmacia/Pfizer.

Figure 1 Average Height over Time, by GH Start Age and Dose.